Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940464 | 1.00 | PYGL (0.49) | PYGLRXRARXRBRXRGCA12 | |
| SCHEMBL3367612 | 0.85 | RXRA (0.54) | PYGLRXRARXRBRXRGCA12 | |
| SCHEMBL14213194 | 0.84 | RXRA (0.49) | PYGLRXRARXRBRXRGCA12 | |
| SCHEMBL1538085 | 0.83 | CA12 (0.41) | PYGLRXRARXRBRXRGCA12 | |
| SCHEMBL1110964 | 0.82 | HTT (0.50) | PYGLRXRARXRBRXRGCA12 | |
| SCHEMBL3648979 | 0.82 | HTT (0.61) | PYGLRXRARXRBRXRGCA12 | |
| SCHEMBL11816083 | 0.82 | RXRA (0.48) | PYGLRXRARXRBRXRGCA12 | |
| SCHEMBL17339467 | 0.82 | PYGL (0.46) | PYGLRXRARXRBRXRGCA1 | |
| SCHEMBL27051473 | 0.82 | ESR1 (0.53) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL6556756 | 0.81 | HSD11B1 (0.48) | PYGLALDH1A1USP2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117887086-A | Application of halogen functionalized metal organic framework material in storage and delivery of fluorine-containing electron special gas | 华为技术有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2024074141-A1 | POROUS MATERIAL AND APPLICATION THEREOF | 华为技术有限公司 | 2024-04-11 | — | — | WO | claimed |
| CN-117013199-A | Fluorinated MOFs-based diaphragm for dendrite-free lithium metal battery and preparation method thereof | 广东工业大学 | 2023-11-07 | — | — | CN | claimed |
| CN-115947949-B | Porous metal organic framework material and synthesis method thereof, adsorbent and method for purifying ethylene | 深圳职业技术学院 | 2023-10-27 | — | — | CN | claimed |
| CN-116371473-A | Composite catalyst for olefin epoxidation reaction, preparation method and application thereof | 大连理工大学宁波研究院 | 2023-07-04 | — | — | CN | claimed |
| CN-115947949-A | Porous metal organic framework material and synthesis method thereof, adsorbent and method for purifying ethylene | 深圳职业技术学院 | 2023-04-11 | — | — | CN | claimed |
| CN-110145200-A | A kind of automatic unit of belt-type Domestic door | 宁波多泰自动门有限公司 | 2019-08-20 | — | — | CN | claimed |
| US-7880026-B2 | preparing a reactant solution containing metal organic framework (MOF) precursors comprise Zn(NO3)2*6H2O and 4,4',4'',4'''-(21H,23H-porphine-5-10-15-20-tetrayl)tetrakis(benzoic acid), the reactant solution includes diethylformamide solvent, exposing to microwave to produce Zn-MOF crystal | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-02-01 | — | — | US | claimed |
| US-20100075123-A1 | WATER REPELLENT METAL-ORGANIC FRAMEWORKS, PROCESS FOR MAKING AND USES REGARDING SAME | University of Illinois - Office of Technology Management (US) | 2010-03-25 | — | — | US | claimed |
| US-20090131643-A1 | Rapid metal organic framework molecule synthesis method | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2009-05-21 | — | — | US | claimed |
| EP-1948353-A2 | HIGH GAIN SELECTIVE PRECONCENTRATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2008057140-A2 | RAPID METAL ORGANIC FRAMEWORK MOLECULE SYNTHESIS METHOD | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-05-15 | — | — | WO | claimed |
| WO-2007044473-A2 | HIGH GAIN SELECTIVE PRECONCENTRATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-19 | — | — | WO | claimed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| CN-116371473-B | Composite catalyst for olefin epoxidation reaction, preparation method and application thereof | 大连理工大学宁波研究院 | 2024-07-09 | — | — | CN | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | PYGL 1466/4885RXRA 4193/4885RXRB 3155/4885 |
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | PYGL 1466/4885RXRA 3874/4885RXRB 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.